1. Scrip
  2. >>Business
  3. >>Earnings

Lilly Sees Massive Growth For Mounjaro Ahead Of Obesity Approval

 
• By Joseph Haas

With more paid prescriptions adding to Mounjaro revenue, along with increasing prescription volume, Lilly is working to increase supply of the GLP-1/GIP agonist as it awaits FDA’s call on a weight-loss indication.

Mounjaro
Mounjaro sales skyrocketed in Q3, driving Lilly's revenue growth • Source: Shutterstock

With Eli Lilly and Company and Novo Nordisk A/S releasing their third quarter financials on the same day, significant focus went to the developing competition in obesity between the two firms – already head-to-head rivals in diabetes for years – with one analyst saying Lilly’s Mounjaro (tirzepatide) is tracking ahead due to significant gross-to-net pricing advancement, even before the GLP-1/GIP agonist has obtained approval as a weight-loss treatment.

Both companies reported strong growth on 2 November for their competing products – Lilly’s Mounjaro, which is approved for type...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

More from Business

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.